The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...
Sage Therapeutics has said it will stop the development ... Last month, Sage reported that Biogen had ducked out of a collaboration on a drug codenamed SAGE-324 for essential tremor, a ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating ...
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...
DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease Therapeutics and Diagnostics: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Alzheimer's Disease Therapeutics and ...
The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma ...
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results